Comparative Pharmacology
Head-to-head clinical analysis: AKNE MYCIN versus BENSULFOID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AKNE MYCIN versus BENSULFOID.
AKNE-MYCIN vs BENSULFOID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin, a macrolide antibiotic, binds to the 50S subunit of bacterial ribosomes and inhibits protein synthesis by blocking translocation of peptidyl-tRNA. Topically, it reduces Propionibacterium acnes colonization and exhibits anti-inflammatory properties.
Unknown; may inhibit Na+/K+-ATPase pump and increase renal sodium excretion
Topical application of 2% solution twice daily to affected areas.
Bensulfoid: not a recognized drug. No data available.
None Documented
None Documented
2-3 hours (normal renal function); up to 24-36 hours in severe renal impairment
Terminal elimination half-life: 12-18 hours in adults with normal renal function; prolonged to 24-48 hours in moderate renal impairment (CrCl 30-50 mL/min).
Primarily renal (60-80% unchanged); minor biliary/fecal (15-30%)
Renal excretion of unchanged drug: 70-80%; biliary/fecal: 15-20%; metabolic inactivation accounts for the remainder.
Category C
Category C
Topical Antibiotic
Topical Antibiotic